PFE vs. AMGN, GILD, MRNA, NVAX, VTRS, ABBV, BMY, JNJ, LLY, and MRK
Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Novavax (NVAX), Viatris (VTRS), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), and Merck & Co., Inc. (MRK). These companies are all part of the "medical" sector.
Pfizer vs. Its Competitors
Pfizer (NYSE:PFE) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.
Amgen has a net margin of 17.39% compared to Pfizer's net margin of 12.62%. Amgen's return on equity of 176.11% beat Pfizer's return on equity.
Pfizer presently has a consensus price target of $29.17, indicating a potential upside of 16.53%. Amgen has a consensus price target of $307.82, indicating a potential upside of 5.95%. Given Pfizer's stronger consensus rating and higher probable upside, analysts clearly believe Pfizer is more favorable than Amgen.
Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
68.4% of Pfizer shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.9%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years and Amgen has increased its dividend for 14 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Pfizer has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
In the previous week, Pfizer had 23 more articles in the media than Amgen. MarketBeat recorded 86 mentions for Pfizer and 63 mentions for Amgen. Pfizer's average media sentiment score of 1.06 beat Amgen's score of 0.99 indicating that Pfizer is being referred to more favorably in the media.
Summary
Pfizer and Amgen tied by winning 10 of the 20 factors compared between the two stocks.
Get Pfizer News Delivered to You Automatically
Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:PFE) was last updated on 7/2/2025 by MarketBeat.com Staff
